Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12‐year retrospective analysis within NETwerk , an ENETS center of excellence
Journal of Neuroendocrinology · 2026-05 · 38 (5)
DOI: 10.1111/jne.70193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 15.05.2026. Verfasst von Laura Mariën und 12 weiteren Autor:innen. Beteiligte Einrichtung: MedGen Group, Center of Medical Genetics, University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Germ-Line Mutation, Genetic Testing. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant tumor predisposition syndrome in which neuroendocrine tumors (NET) represent a major driver of morbidity and mortality. Timely recognition of MEN1 after NET diagnosis enables syndrome‐specific surveillance and cascade testing, yet real‐world evidence on MEN1 testing implementation in oncology pathways remains limited. The aim of this study was to evaluate MEN1 testing practices and assess concordance with guideline‐based indications and nomogram‐predicted risk. A retrospective cohort study was performed within NETwerk, a Belgian ENETS CoE, with patients
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MedGen Group, Center of Medical Genetics, University of Antwerp, Antwerp, Belgium.
- NETwerk-ENETS Center of Excellence, Antwerp-Waasland, Belgium.
- Department of Oncology, Antwerp University Hospital, Antwerp, Belgium.
- Center for Oncological Research, University of Antwerp, Antwerp, Belgium.
- Department of Endocrinology, Antwerp University Hospital, Antwerp, Belgium.
- Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
ORCID-Profile: Laura Mariën, Siddharth Chhajlani, Carlien De Herdt, Wim Demey, Katleen Janssens, Timon Vandamme
Förderung
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Mariën, L., Chhajlani, S., De Herdt, C., Ceulemans, K., Van Hoegaerden, S., Leuridan, M., Van Daele, N., Abrams, P., Demey, W., Ulenaers, M., Lybaert, W., Janssens, K., & Vandamme, T. (2026). Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12‐year retrospective analysis within NETwerk , an ENETS center of excellence. Journal of Neuroendocrinology, 38(5). https://doi.org/10.1111/jne.70193
Vancouver
Mariën L, Chhajlani S, De Herdt C, Ceulemans K, Van Hoegaerden S, Leuridan M, et al. Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12‐year retrospective analysis within NETwerk , an ENETS center of excellence. Journal of Neuroendocrinology. 2026;38(5). doi:10.1111/jne.70193
BibTeX
@article{Marin2026,
author = {Mariën, Laura and Chhajlani, Siddharth and De Herdt, Carlien and Ceulemans, Kobe and Van Hoegaerden, Silke and Leuridan, Morgane and Van Daele, Nathalie and Abrams, Pascale and Demey, Wim and Ulenaers, Marijke and Lybaert, Willem and Janssens, Katleen and Vandamme, Timon},
title = {Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12‐year retrospective analysis within NETwerk , an ENETS center of excellence},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {5},
doi = {10.1111/jne.70193}
}
EUVIMED